{
    "clinical_study": {
        "@rank": "82406", 
        "arm_group": [
            {
                "arm_group_label": "GBS", 
                "arm_group_type": "Active Comparator", 
                "description": "GBS vaccine"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "Evaluate the safety and immunogenicity of the trivalent group B streptococcus vaccine in\n      healthy pregnant women. The study will also evaluate the levels of GBS serotype-specific\n      antibodies in infants, placental transfer from the pregnant women to the infant and levels\n      of antibodies in the breast milk."
        }, 
        "brief_title": "Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "GBS Disease", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Healthy pregnant women 18-40 years of age, inclusive and at 28 0/7 through 34 6/7\n             weeks gestation.\n\n          2. Individuals who intend to breastfeed for at least 90 days postpartum.\n\n          3. Individuals who have given written consent after the nature of the study has been\n             explained according to local regulatory requirements.\n\n          4. Individuals in good health as determined by the outcome of medical history, physical\n             examination and clinical judgment of the investigator.\n\n          5. Individuals who can comprehend and comply with all study procedures and are available\n             for follow-up.\n\n        Exclusion Criteria:\n\n          1. Individuals with history of illness or an ongoing illness that, in the opinion of the\n             investigator, may pose additional risk to the subject if she participates in the\n             study.\n\n          2. Individuals with known hypersensitivity to any component of the vaccine.\n\n          3. Individuals who received or plan to receive any licensed vaccine within 14 days\n             before or after the study vaccine with the  exception of inactivated influenza\n             vaccine which may be administered up to 7 days before or after study vaccine.\n\n          4. Individuals with an infection requiring systemic antibiotic or antiviral treatment\n             within 7 days prior to Study Day 1.\n\n          5. Individuals determined as high risk for serious obstetrical complication, including:\n\n               -  Gestational hypertension, as defined by American College of Obstetricians and\n                  Gynecologists guidelines (ACOG Practice Bulletin 2012)\n\n               -  Gestational diabetes which is not controlled by diet and exercise as per\n                  American College of Obstetricians and Gynecologists guidelines (ACOG Practice\n                  Bulletin 2013)\n\n               -  Pre-eclampsia or eclampsia as defined by American College of Obstetricians and\n                  Gynecologists guidelines (ACOG practice bulletin, 2002)\n\n               -  HIV infection\n\n               -  Obesity class II or greater (pre-pregnancy BMI\u226535.0)\n\n               -  multiple pregnancy\n\n          6. Individuals with behavioral or cognitive impairment or psychiatric disease that, in\n             the opinion of the investigator, may interfere with the subject's ability to\n             participate in the study.\n\n          7. Individuals who are not able to comprehend and to follow all required study\n             procedures for the whole period of the study.\n\n          8. Individuals with known or suspected impairment of the immune system including known\n             or suspected HIV infection or HIV-related disease, a history of or an active\n             autoimmune disorder and receipt of immunosuppressive therapy.\n\n          9. Long term use of glucocorticoids, including oral or parenteral prednisone \u2265 20 mg/day\n             or equivalent for more than 2 consecutive weeks (or 2 weeks total) within 30 days\n             prior to enrollment. Use of inhaled, intranasal, or topical corticosteroids is\n             allowed.\n\n         10. Individuals participating in any clinical trial with another investigational product\n             during the pregnancy or intent to participate in another clinical study at any time\n             during the conduct of this study.\n\n         11. Pregnant with a fetus with a known or suspected congenital anomaly\n\n         12. Individuals who are acting as study personnel or immediate family members (brother,\n             sister, child, parent) or the spouse of study personnel.\n\n         13. Individuals with a fever (oral temperature \u2265 38\u00b0C/100.4 \u00b0F) within 3 days prior to\n             intended study vaccination.\n\n         14. Individuals with a history of culture confirmed GBS case in the infant(s) previously\n             born to her."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "75", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02046148", 
            "org_study_id": "V98_12"
        }, 
        "intervention": [
            {
                "arm_group_label": "GBS", 
                "description": "Trivalent GBS vaccine", 
                "intervention_name": "GBS vaccine", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Normal saline", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Maternal vaccine", 
            "GBS", 
            "pregnant women", 
            "IgG", 
            "IgA"
        ], 
        "lastchanged_date": "March 24, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Durham", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27710"
                }, 
                "name": "Duke University Medical Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase II, Multicenter, Randomized, Observer-Blind, Controlled Study to Evaluate Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women", 
        "overall_contact": {
            "last_name": "Novartis Drug Information Services", 
            "phone": "+1 800 244 7668"
        }, 
        "overall_official": {
            "affiliation": "Novartis Vaccines", 
            "last_name": "Novartis Vaccines", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "To evaluate serotype-specific (Ia, Ib and III) GBS serum IgG antibody levels in vaccinated mothers and infant", 
                "measure": "Concentration of GBS IgG levels in infant serum at Delivery and Days 42 and 90 of age", 
                "safety_issue": "No", 
                "time_frame": "Birth, Days 42 and 90 of infant"
            }, 
            {
                "measure": "Concentration of GBS IgG levels in maternal serum at prevaccination, Study Day 31, at Delivery and at Days 42 and 90 postpartum", 
                "safety_issue": "No", 
                "time_frame": "Day 1 prevaccination, Day 31 postvaccination, delivery, Days 42 and 90 postpartum"
            }, 
            {
                "measure": "Ratio relative to prevaccination levels of maternal serum GBS IgG antibody levels as measured at Study Day 31, Delivery and at Days 42 and 90 postpartum", 
                "safety_issue": "No", 
                "time_frame": "Study Day 31, Delivery and at Days 42 and 90 postpartum"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02046148"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To evaluate the relationship of serotype-specific (Ia, Ib and III) GBS IgG antibody levels in the infant and maternal serum", 
            "measure": "Ratio of GBS antibody levels in infant serum relative to maternal serum at the time of Delivery", 
            "safety_issue": "No", 
            "time_frame": "Delivery"
        }, 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Vaccines", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}